Life sciences companies face challenges due to inflation, geopolitical tensions, and antitrust monitoring. They have to adjust their strategies to protect shareholder value amidst the downturn. The Inflation Reduction Act impacts drug prices, adding to the difficulties many life sciences boards face. Boards must streamline their management processes and avoid wasting precious time.

In this guide, we share best practices to help boards work more efficiently, protect the company from risks and more.